Health & Medicinearticle2026-09-02

Guidance for laboratory implementation, governance and continuous assurance of artificial intelligence in histopathology

Open access0 citations

Abstract

Abstract Artificial intelligence (AI) is rapidly transforming histopathology, with applications ranging from workflow optimisation and quality assurance to tumour diagnosis, grading, biomarker assessment and estimation of prognosis. While numerous AI algorithms have demonstrated promising analytical and clinical performance, pathology laboratories are increasingly adopting commercially available AI systems with regulatory-approval rather than developing their own algorithms. Existing guidance largely focuses on AI development, validation and regulatory approval, with comparatively little practical direction on the local verification, governance and ongoing assurance required for safe routine clinical implementation. This paper proposes a practical framework for the clinical implementation of AI specifically within pathology laboratories. Rather than addressing AI development, it focuses on the responsibilities of laboratories adopting established AI systems into clinical practice. The framework distinguishes AI applications according to their intended clinical function, recognising that diagnostic applications, biomarker evaluation, workflow optimisation and generative AI applications require different implementation, verification, governance and quality assurance strategies. It further distinguishes algorithm validation, local verification and continuous assurance as complementary stages of implementation and advocates a function-based, risk-proportionate approach integrated within existing laboratory quality management systems. Practical recommendations are provided for workflow integration, interoperability, human oversight, user competency, performance monitoring, incident management, software updates and proportionate re-verification throughout the AI operational lifecycle. By extending implementation beyond regulatory approval, this guidance complements existing AI development and regulatory frameworks rather than replacing them. It provides a practical governance framework for pathology laboratories, professional organisations, accreditation bodies, and healthcare providers to support the safe, standardised, and sustainable integration of AI into routine histopathology while maintaining diagnostic quality, patient safety, and clinical governance.

// Source

View paper (DOI)Open access versionOpenAlexArchiv für Pathologische Anatomie und Physiologie und für Klinische MedicinPublished 2026-09-02

Authors: Emad A. Rakha, Jelle Wesseling, Anikó Kovács, Aleš Ryška, Elena Provenzano, Gábor Cserni, Zsuzsanna Varga, Zsuzsanna Bagó-Horváth, Emmanuelle Charafe‐Jauffret, Janina Kulka, Carolien H. M. van Deurzen, António Polónia, Thomas Decker, P J van Diest, Cecily Quinn, On behalf of the European Working Group for Breast Screening Pathology (EWGBSP).

Institutions: Leiden University Medical Center, University of Nottingham, University Hospital Münster, Semmelweis University, Sahlgrenska University Hospital, University of Szeged, Bács-Kiskun Megyei Kórház, Charles University, University Hospital Zurich, Medical University of Vienna, Erasmus MC Cancer Institute, Abu Dhabi Health Services, Cambridge University Hospitals NHS Foundation Trust, University Medical Center Utrecht, Addenbrooke's Hospital, St. Vincent's University Hospital, Abu Dhabi National Oil (United Arab Emirates), Royal Irish Academy, Fernando Pessoa University, Institut Paoli-Calmettes, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital